Arrowhead Research has filed an application with regulators to begin a Phase I trial of its alpha-1 antitrypsin deficiency (AAT) drug ARC-AAT in Australia.
Upon approval of its application, Arrowhead said that it will start the trial of the drug in up to 48 healthy volunteers and AAT patients to evaluate ARC-AAT’s safety, tolerability, pharmacokinetics, and effect on circulating alpha-1 antitrypsin levels.
